학술논문
Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors
Document Type
Article
Author
Conlon, K.; Waldmann, T.A.; Watson, D.C.; Valentin, A.; Pavlakis, G.N.; Bergamaschi, C.; Felber, B.K.; Peer, C.J.; Figg, W.D.; Potter, E.L.; Roederer, M.; Mcneel, D.G.; Thompson, J.A.; Gupta, S.; Leidner, R.; Wang-Gillam, A.; Parikh, N.S.; Long, D.; Kurtulus, S.; Ho Lee, L.; Chowdhury, N.R.; Bender, F.
Source
In: Journal for ImmunoTherapy of Cancer . (Journal for ImmunoTherapy of Cancer, 19 November 2021, 9(11))
Subject
Language
English
ISSN
20511426